Guo-Fu Li

Dr. Guo-Fu Li

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
GYGuo Yu
Guo Yu
GLGuo-Fu Li
Guo-Fu Li
JMJohn S. Markowitz
John S. Markowitz
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children (≥6 years of age), adolescents, and adults. Its metabolism and disposition are fairly complex, and primarily governed by cytochrome P450 (CYP) 2D6 (CYP2D6), whose protein expression varies substantially from person to person, and by race and ethnicity because of genetic polymorphism. These differences can be substantial, resulting in 8–10-fold differences in atomoxetine exposure between CYP2D6 poor metabolizers and extensive metabolizers. In this review, we have attempted to revisit and analyze all published clinical pharmacokinetic data on atomoxetine inclusive of public access documents from the new drug application submitted to the United States Food and Drug Administration (FDA). The present review focuses on atomoxetine metabolism, disposition, and genetic polymorphisms of CYP2D6 as they specifically relate to atomoxetine, and provides an in-depth discussion of the fundamental pharmacokinetics of the drug including its absorption, distribution, metabolism, and excretion in pediatric and adult populations. Further, a summary of relationships between genetic variants of CYP2D6 and to some degree, CYP2C19, are provided with respect to atomoxetine plasma concentrations, central nervous system (CNS) pharmacokinetics, and associated clinical implications for pharmacotherapy. Lastly, dosage adjustments based on pharmacokinetic principles are discussed.

10 June 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
XSXiang-Hong Sun
Xiang-Hong Sun
YWYu-Tong Wang
Yu-Tong Wang
GLGuo-Fu Li
Guo-Fu Li
NZNan Zhang
Nan Zhang
LFLing Fan
Ling Fan
Background: Hepatocellular carcinoma (HCC) is a common tumor characterized by high morbidity and mortality rates. The importance of circRNA in cancer diagnosis has been established. The study aimed to identify differentially-expressed circRNAs (DECs) in human blood exosomes from patients with HCC and to investigate their diagnostic value. Methods: The circRNA expression profiles of HCC and normal human blood samples were downloaded and processed from the exoRBase database. At the cutoff criteria of a fold change (FC) > 2.0 and P < 0.05, DECs were screened utilizing the limma package in the R software. A receiver operator characteristic curve (ROC) was used to study its diagnostic value. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis was performed to confirm the three-circRNAs expression in the blood samples with HCC. Various bioinformatics tools were used to characterize the potential biological pathways induced by circRNAs. Results: Compared with the normal samples, seven up-regulated and five down-regulated circRNAs were determined in the HCC samples. ROC analyses demonstrated that hsa_circ_0004001, hsa_circ_0004123, hsa_circ_0075792, and a combination of the three biomarkers exhibited higher sensitivity and specificity. The qRT-PCR confirmed that the three circRNAs were upregulated in the blood samples with HCC. Chi squared tests implied that the expression of three circRNAs was positively correlated with the TNM stage and tumor size. The circRNAs participated in VEGF/VEGFR, PI3K/Akt, mTOR, and Wnt signaling pathways by targeting miRNAs. Conclusions: The study established the existence of seven up-regulated and five down-regulated circRNAs in HCC. Additionally, hsa_circ_0004001, hsa_circ_0004123, hsa_circ_0075792, and a combination of the three were utilized as valuable diagnostic biomarkers in HCC.

3 September 2014 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
GYGuo Yu
Guo Yu
QZQing-Shan Zheng
Qing-Shan Zheng
GLGuo-Fu Li
Guo-Fu Li

22 October 2012 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
GLGuo-Fu Li
Guo-Fu Li
KWKun Wang
Kun Wang
RCRui Chen
Rui Chen
HZHao-Ru Zhao
Hao-Ru Zhao
JYJin Yang
Jin Yang
QZQing-Shan Zheng
Qing-Shan Zheng

10 November 2020 in Gut
Verified
Journal Article
Open access
PDF file
GLGuo-Fu Li
Guo-Fu Li
XAXiao-Xiao An
Xiao-Xiao An
YYYichao Yu
Yichao Yu
LJLi-Rong Jiao
Li-Rong Jiao
DCDaniele Canarutto
Daniele Canarutto
Yin XiaoYin Xiao
Yin Xiao

2 December 2019 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
JGJia-Qin Gu
Jia-Qin Gu
YGYun-Peng Guo
Yun-Peng Guo
Zheng JiaoZheng Jiao
Zheng Jiao
JDJun-Jie Ding
Jun-Jie Ding
GLGuo-Fu Li
Guo-Fu Li